title: Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.
abstract: The 5-HT(7) receptor is targeted by several new antipsychotics such as clozapine and risperidone. We studied the effect of R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine (SB-258741), a specific 5-HT(7) receptor antagonist, in three models for positive symptoms, D-amphetamine-induced hyperactivity and D-amphetamine- and phencyclidine (PCP)-disrupted prepulse inhibition (PPI) in rats, with the aim of investigating the role of this receptor in the clinical effect of antipsychotics. We also tested this compound in a model for negative symptoms, PCP-disrupted social interaction (SIT) in rats. Induction of side effects by this compound was evaluated by testing its potency to reduce spontaneous motility and to induce catalepsy in rats. The effect of SB-258741 was compared to risperidone in all models. This study showed that SB-258741 had no beneficial effect on PCP-disrupted SIT. SB-258741 did not reverse D-amphetamine-disrupted PPI; however, it dose-dependently normalised PCP-disrupted PPI. SB-258741 antagonised D-amphetamine-induced hyperactivity but reduced motility of rats at similar doses. Thus, this specific 5-HT(7) receptor antagonist brought a clear positive outcome in only one model for positive symptoms of schizophrenia and had no beneficial effect in the model for negative symptoms. Consequently, it is clear that SB-258741 affects the PPI phenomenon but is not expected to have an antipsychotic effect on its own in clinic.
authors.affiliation: Psychopharmacology--Psychosis Department, H. Lundbeck A/S, Ottiliavej 7-9, DK-2500, Valby, Denmark. brp@lundbeck.com
authors.forename: B
authors.initials: B
authors.lastname: Pouzet
authors.forename: M
authors.initials: M
authors.lastname: Didriksen
authors.forename: J
authors.initials: J
authors.lastname: Arnt
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011985:Receptors, Serotonin / Q000187:drug effects*; D013216:Reflex, Startle / Q000187:drug effects; D018967:Risperidone / Q000494:pharmacology; D012559:Schizophrenia / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D012919:Social Behavior; D014105:Tosyl Compounds / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D010880:Piperidines; D011759:Pyrrolidines; D011985:Receptors, Serotonin; C462239:SB258741; D012702:Serotonin Antagonists; D014105:Tosyl Compounds; C104425:serotonin 7 receptor; D018967:Risperidone; D003913:Dextroamphetamine